{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T10:09:46Z","timestamp":1790330986941,"version":"4.1.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"crossref","award":["20224BAB216011"],"award-info":[{"award-number":["20224BAB216011"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the major science and technology R & D projects of Jiangxi Province","award":["20213AAG01013"],"award-info":[{"award-number":["20213AAG01013"]}]},{"name":"the National Nature Science Foundation in China","award":["82472225"],"award-info":[{"award-number":["82472225"]}]},{"name":"Jiangxi Province Science and Technology Innovation Talent Project","award":["jxsq2023201037"],"award-info":[{"award-number":["jxsq2023201037"]}]},{"name":"Science and technology innovation base plan of Jiangxi Province-Key Laboratory of Jiangxi Province for Transfusion Medicine","award":["2024SSY06171"],"award-info":[{"award-number":["2024SSY06171"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Gastric cancer (GC) frequently shows malignant progression and resistance to chemotherapy due to complex molecular regulatory processes, leading to a poor prognosis. Our study elucidates that PDZ and LIM domain protein 4 (PDLIM4) are highly expressed in GC, thereby promoting the malignant progression and cisplatin (DDP) resistance of GC. Mechanistically, PDLIM4, via its C-terminal and intermediate regions, impedes the ubiquitination and proteasomal degradation of Heat Shock Protein 70 (HSP70) by competing with the STIP1 homology and U-box containing protein 1 (STUB1), subsequently activating the MAPK signaling pathway. In addition, we synthesized lipid nanoparticles (LNPs), including siPDLIM4 LNPs, DDP LNPs, and siPDLIM4\/DDP LNPs. Experiments further indicated that siPDLIM4 LNPs and DDP LNPs have an anti-tumor property, while siPDLIM4\/DDP LNPs exhibit the most significant anti-tumor efficacy. In summary, our research identifies PDLIM4 as a facilitator of malignant progression and DDP resistance in GC cells, targeting PDLIM4 not only inhibits the malignant progression of GC, but also provides an effective strategy to enhance DDP sensitivity in GC treatment, emphasizing its potential as a therapeutic target.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1186\/s12951-025-03720-4","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:42:22Z","timestamp":1760168542000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["PDLIM4 drives gastric cancer malignant progression and cisplatin resistance by inhibiting HSP70 ubiquitination and degradation via competitive interaction with STUB1"],"prefix":"10.1186","volume":"23","author":[{"given":"Chao","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linwei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiyu","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sifan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,11]]},"reference":[{"key":"3720_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca-a Cancer Journal for Clinicians. 2024;74:229\u201363.","journal-title":"Ca-a Cancer Journal for Clinicians"},{"key":"3720_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00052-2","author":"R Sundar","year":"2025","unstructured":"Sundar R, Nakayama I, Markar SR, Shitara K, van Laarhoven HWM, Janjigian YY, et al. Gastric cancer. Lancet (London, England). 2025. https:\/\/doi.org\/10.1016\/S0140-6736(25)00052-2.","journal-title":"Lancet (London, England)"},{"key":"3720_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s11658-021-00271-y","author":"D Fu","year":"2021","unstructured":"Fu D, Wang C, Yu L, Yu R. Induction of ferroptosis by ATF3 elevation alleviates cisplatin resistance in gastric cancer by restraining Nrf2\/Keap1\/xCT signaling. Cell Mol Biol Lett. 2021. https:\/\/doi.org\/10.1186\/s11658-021-00271-y.","journal-title":"Cell Mol Biol Lett"},{"key":"3720_CR4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.canlet.2011.06.024","volume":"311","author":"HJ Cho","year":"2011","unstructured":"Cho HJ, Baek KE, Park S-M, Kim I-K, Nam I-K, Choi Y-L, et al. RhoGDI2 confers gastric cancer cells resistance against cisplatin-induced apoptosis by upregulation of Bcl-2 expression. Cancer Lett. 2011;311:48\u201356.","journal-title":"Cancer Lett"},{"key":"3720_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202404994","author":"X He","year":"2024","unstructured":"He X, Zhong L, Wang N, Zhao B, Wang Y, Wu X, et al. Gastric cancer actively remodels mechanical microenvironment to promote chemotherapy resistance via MSCs-mediated mitochondrial transfer. Adv Sci. 2024. https:\/\/doi.org\/10.1002\/advs.202404994.","journal-title":"Adv Sci"},{"key":"3720_CR6","doi-asserted-by":"publisher","unstructured":"Dong D, Yu X, Xu J, Yu N, Liu Z, Sun Y. Cellular and molecular mechanisms of gastrointestinal cancer liver metastases and drug resistance. Drug Resist Updates. 2024. https:\/\/doi.org\/10.1016\/j.drup.2024.101125","DOI":"10.1016\/j.drup.2024.101125"},{"key":"3720_CR7","doi-asserted-by":"publisher","DOI":"10.1172\/JCI158705","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Chen Y, Shi Y, Wu L, Tan Y, Li T, et al. FAM117B promotes gastric cancer growth and drug resistance by targeting the KEAP1\/NRF2 signaling pathway. J Clin Invest. 2023. https:\/\/doi.org\/10.1172\/JCI158705.","journal-title":"J Clin Invest"},{"key":"3720_CR8","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1100\/tsw.2007.232","volume":"7","author":"AJWt Velthuis","year":"2007","unstructured":"Velthuis AJWt, Bagowski CP. PDZ and LIM domain-encoding genes: molecular interactions and their role in development. TheScientificWorldJOURNAL. 2007;7:1470\u201392.","journal-title":"TheScientificWorldJOURNAL"},{"key":"3720_CR9","doi-asserted-by":"publisher","first-page":"26849","DOI":"10.1074\/jbc.M111.241554","volume":"286","author":"OA Guryanova","year":"2011","unstructured":"Guryanova OA, Drazba JA, Frolova EI, Chumakov PM. Actin cytoskeleton remodeling by the alternatively spliced isoform of PDLIM4\/RIL protein. J Biol Chem. 2011;286:26849\u201359.","journal-title":"J Biol Chem"},{"key":"3720_CR10","doi-asserted-by":"publisher","unstructured":"Jia Y, Shi H, Cao Y, Feng W, Li M, Li X. PDZ and LIM domain protein 4 suppresses the growth and invasion of ovarian cancer cells via inactivation of STAT3 signaling. Life Sci. 2019. https:\/\/doi.org\/10.1016\/j.lfs.2019.116715","DOI":"10.1016\/j.lfs.2019.116715"},{"key":"3720_CR11","doi-asserted-by":"crossref","unstructured":"Vanaja DK, Ballman KV, Morlan BW, Cheville JC, Neumann RM, Lieber MM, et al. Xxaaai>PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer. Clin Cancer Res. 2006;12:1128\u201336.","DOI":"10.1158\/1078-0432.CCR-05-2072"},{"key":"3720_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/biom13040601","author":"K Zhao","year":"2023","unstructured":"Zhao K, Zhou G, Liu Y, Zhang J, Chen Y, Liu L, et al. HSP70 family in cancer: signaling mechanisms and therapeutic advances. Biomolecules. 2023. https:\/\/doi.org\/10.3390\/biom13040601.","journal-title":"Biomolecules"},{"key":"3720_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2024.01.001","author":"S Leone","year":"2024","unstructured":"Leone S, Srivastava A, Herrero-Ruiz A, Hummel B, Tittel L, Campalastri R, et al. HSP70 binds to specific non-coding RNA and regulates human RNA polymerase III. Mol Cell. 2024. https:\/\/doi.org\/10.1016\/j.molcel.2024.01.001.","journal-title":"Mol Cell"},{"key":"3720_CR14","doi-asserted-by":"publisher","unstructured":"Zhang Z, Jing J, Ye Y, Chen Z, Jing Y, Li S, et al. Characterization of the dual functional effects of heat shock proteins (HSPs) in cancer hallmarks to aid development of HSP inhibitors. Genome Med. 2020. https:\/\/doi.org\/10.1186\/s13073-020-00795-6.","DOI":"10.1186\/s13073-020-00795-6"},{"key":"3720_CR15","doi-asserted-by":"publisher","unstructured":"Qian W, Zhang X, Yuan D, Wu Y, Li H, Wei L, et al. USP8 and Hsp70 regulate endoreplication by synergistically promoting Fzr deubiquitination and stabilization. Sci Adv. 2025. https:\/\/doi.org\/10.1126\/sciadv.adq9111.","DOI":"10.1126\/sciadv.adq9111"},{"key":"3720_CR16","doi-asserted-by":"crossref","unstructured":"Ferretti GDS, Quaas CE, Bertolini I, Zuccotti A, Saatci O, Kashatus JA, et al. HSP70-mediated mitochondrial dynamics and autophagy represent a novel vulnerability in pancreatic cancer. Cell Death Differ. 2024;31:881\u201396.","DOI":"10.1038\/s41418-024-01310-9"},{"key":"3720_CR17","doi-asserted-by":"crossref","unstructured":"Fiengo L, Lauro G, Bellone ML, Bifulco G, Dal Piaz F, De Tommasi N. The plant diterpene epoxysiderol targets Hsp70 in cancer cells, affecting its ATPase activity and reducing its translocation to plasma membrane. Int J Biol Macromol. 2021;189:262\u201370.","DOI":"10.1016\/j.ijbiomac.2021.08.138"},{"key":"3720_CR18","doi-asserted-by":"crossref","unstructured":"Lei Z, Xia X, He Q, Luo J, Xiong Y, Wang J, et al. HSP70 promotes tumor progression by stabilizing Skp2 expression in gastric cancer cells. Mol Carcinog. 2021;60:826\u201339.","DOI":"10.1002\/mc.23346"},{"key":"3720_CR19","doi-asserted-by":"crossref","unstructured":"Sheng L, Tang T, Liu Y, Ma Y, Wang Z, Tao H, et al. Inducible HSP70 antagonizes cisplatin-induced cell apoptosis through inhibition of the MAPK signaling pathway in HGC-27 cells. Int J Mol Med. 2018;42:2089\u201397.","DOI":"10.3892\/ijmm.2018.3789"},{"key":"3720_CR20","doi-asserted-by":"publisher","unstructured":"Liu Y, Zhou H, Tang X. STUB1\/CHIP: New insights in cancer and immunity. Biomed Pharmacother. 2023. https:\/\/doi.org\/10.1016\/j.biopha.2023.115190.","DOI":"10.1016\/j.biopha.2023.115190"},{"key":"3720_CR21","doi-asserted-by":"publisher","unstructured":"Liao Y, Liu Y, Yu C, Lei Q, Cheng J, Kong W, et al. HSP90\u03b2 impedes STUB1-induced ubiquitination of YTHDF2 to drive sorafenib resistance in hepatocellular carcinoma. Adv Sci. 2023. https:\/\/doi.org\/10.1002\/advs.202302025.","DOI":"10.1002\/advs.202302025"},{"key":"3720_CR22","doi-asserted-by":"publisher","unstructured":"Sun X, Zhang Q, Lin X, Shu P, Gao X, Shen K. Imatinib induces ferroptosis in gastrointestinal stromal tumors by promoting STUB1-mediated GPX4 ubiquitination. Cell Death Dis. 2023. https:\/\/doi.org\/10.1038\/s41419-023-06300-2.","DOI":"10.1038\/s41419-023-06300-2"},{"key":"3720_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2017.00415","author":"TM Morey","year":"2017","unstructured":"Morey TM, Winick-Ng W, Seah C, Rylett RJ. Chaperone-mediated regulation of choline acetyltransferase protein stability and activity by HSC\/HSP70, HSP90, and p97\/VCP. Front Mol Neurosci. 2017. https:\/\/doi.org\/10.3389\/fnmol.2017.00415.","journal-title":"Front Mol Neurosci"},{"key":"3720_CR24","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.immuni.2013.08.006","volume":"39","author":"Z Chen","year":"2013","unstructured":"Chen Z, Barbi J, Bu S, Yang H-Y, Li Z, Gao Y, et al. The ubiquitin ligase Stub1 negatively modulates regulatory T cell suppressive activity by promoting degradation of the transcription factor Foxp3. Immunity. 2013;39:272\u201385.","journal-title":"Immunity"},{"key":"3720_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07178-x","author":"C Liu","year":"2018","unstructured":"Liu C, Lou W, Yang JC, Liu L, Armstrong CM, Lombard AP, et al. Proteostasis by STUB1\/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer. Nat Commun. 2018. https:\/\/doi.org\/10.1038\/s41467-018-07178-x.","journal-title":"Nat Commun"},{"key":"3720_CR26","doi-asserted-by":"publisher","first-page":"4437","DOI":"10.7150\/thno.34953","volume":"9","author":"C Hong","year":"2019","unstructured":"Hong C, Wang D, Liang J, Guo Y, Zhu Y, Xia J, et al. Novel ginsenoside-based multifunctional liposomal delivery system for combination therapy of gastric cancer. Theranostics. 2019;9:4437\u201349.","journal-title":"Theranostics"},{"key":"3720_CR27","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41565-022-01266-2","volume":"18","author":"Y Chen","year":"2023","unstructured":"Chen Y, Huang Y, Li Q, Luo Z, Zhang Z, Huang H, et al. Targeting Xkr8 via nanoparticle-mediated in situ co-delivery of siRNA and chemotherapy drugs for cancer immunochemotherapy. Nat Nanotechnol. 2023;18:193.","journal-title":"Nat Nanotechnol"},{"key":"3720_CR28","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/j.apsb.2022.07.011","volume":"13","author":"K Butowska","year":"2023","unstructured":"Butowska K, Han X, Gong N, El-Mayta R, Haley RM, Xue L, et al. Doxorubicin-conjugated siRNA lipid nanoparticles for combination cancer therapy. Acta Pharm Sin B. 2023;13:1429\u201337.","journal-title":"Acta Pharm Sin B"},{"key":"3720_CR29","doi-asserted-by":"publisher","unstructured":"van Der Meel R, Chen S, Zaifman J, Kulkarni JA, Zhang XRS, Tam YK, et al. Modular Lipid Nanoparticle Platform Technology for siRNA and Lipophilic Prodrug Delivery. Small. 2021. https:\/\/doi.org\/10.1002\/smll.202103025","DOI":"10.1002\/smll.202103025"},{"key":"3720_CR30","doi-asserted-by":"crossref","unstructured":"Anthiya S, Ozturk SC, Yanik H, Tavukcuoglu E, Sahin A, Datta D, et al. Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors. J Control Release. 2023;357:67\u201383.","DOI":"10.1016\/j.jconrel.2023.03.016"},{"key":"3720_CR31","doi-asserted-by":"crossref","unstructured":"Moukhtari SHE, Garbayo E, Amundarain A, Pascual-Gil S, Carrasco-Leon A, Prosper F, et al. Lipid nanoparticles for siRNA delivery in cancer treatment. J Control Release. 2023;361:130\u201346.","DOI":"10.1016\/j.jconrel.2023.07.054"},{"key":"3720_CR32","doi-asserted-by":"publisher","unstructured":"Wu S, Lu J. Liposome-enabled nanomaterials for muscle regeneration. Small Methods. 2025. https:\/\/doi.org\/10.1002\/smtd.202402154.","DOI":"10.1002\/smtd.202402154"},{"key":"3720_CR33","doi-asserted-by":"publisher","unstructured":"Park W, Choi J, Kim M, Yang Y, Kweon D-H. Apolipoprotein Fusion Enables Spontaneous Functionalization of mRNA Lipid Nanoparticles with Antibody for Targeted Cancer Therapy. Mol Ther. 2025. https:\/\/doi.org\/10.1021\/acsnano.4c16562","DOI":"10.1021\/acsnano.4c16562"},{"key":"3720_CR34","doi-asserted-by":"publisher","unstructured":"Deng S, Hu L, Chen G, Ye J, Xiao Z, Guan T, et al. A PD-L1 siRNA-loaded boron nanoparticle for targeted cancer radiotherapy and immunotherapy. Adv Mater. 2025. https:\/\/doi.org\/10.1002\/adma.202419418.","DOI":"10.1002\/adma.202419418"},{"key":"3720_CR35","doi-asserted-by":"crossref","unstructured":"Guan J, Sun J, Sun F, Lou B, Zhang D, Mashayekhi V, et al. Hypoxia-induced tumor cell resistance is overcome by synergistic GAPDH-siRNA and chemotherapy co-delivered by long-circulating and cationic-interior liposomes. Nanoscale. 2017;9:9190\u2013201.","DOI":"10.1039\/C7NR02663C"},{"key":"3720_CR36","doi-asserted-by":"publisher","unstructured":"Li Q, Qin T, Bi Z, Hong H, Ding L, Chen J, et al. Rac1 activates non-oxidative pentose phosphate pathway to induce chemoresistance of breast cancer. Nat Commun. 2020. https:\/\/doi.org\/10.1038\/s41467-020-15308-7.","DOI":"10.1038\/s41467-020-15308-7"},{"key":"3720_CR37","doi-asserted-by":"crossref","unstructured":"Meng H, Li R, Xie Y, Mo Z, Zhai H, Zhang G, et al. Nanoparticles mediated circROBO1 silencing to inhibit hepatocellular carcinoma progression by modulating miR-130a-5p\/CCNT2 axis. Int J Nanomedicine. 2023;18:1677\u201393.","DOI":"10.2147\/IJN.S399318"},{"key":"3720_CR38","doi-asserted-by":"publisher","first-page":"4756","DOI":"10.1039\/D2BM00684G","volume":"10","author":"J Ding","year":"2022","unstructured":"Ding J, Kang X, Feng M, Tan J, Feng Q, Wang X, et al. A novel active mitochondrion-selective fluorescent probe for the NIR fluorescence imaging and targeted photodynamic therapy of gastric cancer. Biomater Sci. 2022;10:4756\u201363.","journal-title":"Biomater Sci"},{"key":"3720_CR39","doi-asserted-by":"publisher","first-page":"4659","DOI":"10.2147\/IJN.S367975","volume":"17","author":"Y Liang","year":"2022","unstructured":"Liang Y, Guo W, Li C, Shen G, Tan H, Sun P, et al. Tumor-Targeted Polydopamine-Based Nanoparticles for Multimodal Mapping Following Photothermal Therapy of Metastatic Lymph Nodes. Int J Nanomed. 2022;17:4659\u201375.","journal-title":"Int J Nanomed"},{"key":"3720_CR40","doi-asserted-by":"publisher","first-page":"44","DOI":"10.62347\/GTZZ9726","volume":"15","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Li J, Chen P, Li Z, Yu Y. Evaluation of 18F-FAPI-42-RGD as a novel dual-targeting PET tracer in gastric cancer xenograft models. Am J Nucl Med Mol Imaging. 2025;15:44\u201354.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"3720_CR41","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1080\/07357900802406319","volume":"27","author":"DK Vanaja","year":"2009","unstructured":"Vanaja DK, Grossmann ME, Cheville JC, Gazi MH, Gong A, Zhang JS, et al. PDLIM4, an actin binding protein, suppresses prostate cancer cell growth. Cancer Invest. 2009;27:264\u201372.","journal-title":"Cancer Invest"},{"key":"3720_CR42","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/j.str.2022.10.001","volume":"30","author":"MD Healy","year":"2022","unstructured":"Healy MD, Sacharz J, McNally KE, McConville C, Tillu VA, Hall RJ, et al. Proteomic identification and structural basis for the interaction between sorting nexin SNX17 and PDLIM family proteins. Structure. 2022;30:1590.","journal-title":"Structure"},{"key":"3720_CR43","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1042\/BST20220804","volume":"51","author":"MD Healy","year":"2023","unstructured":"Healy MD, Collins BM. The PDLIM family of actin-associated proteins and their emerging role in membrane trafficking. Biochem Soc Trans. 2023;51:2005\u201316.","journal-title":"Biochem Soc Trans"},{"key":"3720_CR44","doi-asserted-by":"crossref","unstructured":"Chen H-N, Yuan K, Xie N, Wang K, Huang Z, Chen Y, et al. PDLIM1 stabilizes the E-cadherin\/\u03b2-catenin complex to prevent epithelial-mesenchymal transition and metastatic potential of colorectal cancer cells. Cancer Res. 2016;76:1122\u201334.","DOI":"10.1158\/0008-5472.CAN-15-1962"},{"key":"3720_CR45","doi-asserted-by":"publisher","unstructured":"Fang L, Liu C, Jiang Z-z, Wang M, Geng K, Xu Y, et al. Annexin A1 binds PDZ and LIM domain 7 to inhibit adipogenesis and prevent obesity. Signal Transduct Target Ther. 2024. https:\/\/doi.org\/10.1038\/s41392-024-01930-0.","DOI":"10.1038\/s41392-024-01930-0"},{"key":"3720_CR46","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.15252\/embj.201796699","volume":"36","author":"Y Sha","year":"2017","unstructured":"Sha Y, Rao L, Settembre C, Ballabio A, Eissa NT. STUB1 regulates TFEB-induced autophagy-lysosome pathway. EMBO J. 2017;36:2544\u201352.","journal-title":"EMBO J"},{"key":"3720_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-024-07127-z","author":"L Zhao","year":"2024","unstructured":"Zhao L, Yang H, Wang Y, Yang S, Jiang Q, Tan J, et al. STUB1 suppresses paclitaxel resistance in ovarian cancer through mediating HOXB3 ubiquitination to inhibit PARK7 expression. Commun Biol. 2024. https:\/\/doi.org\/10.1038\/s42003-024-07127-z.","journal-title":"Commun Biol"},{"key":"3720_CR48","doi-asserted-by":"publisher","unstructured":"Chen J, Wang D, Wu G, Xiong F, Liu W, Wang Q, et al. STUB1-mediated K63-linked ubiquitination of UHRF1 promotes the progression of cholangiocarcinoma by maintaining DNA hypermethylation of PLA2G2A. J Exp Clin Cancer Res. 2024. https:\/\/doi.org\/10.1186\/s13046-024-03186-6.","DOI":"10.1186\/s13046-024-03186-6"},{"key":"3720_CR49","doi-asserted-by":"publisher","unstructured":"Soss SE, Rose KL, Hill S, Jouan S, Chazin WJ. Biochemical and proteomic analysis of ubiquitination of Hsc70 and Hsp70 by the E3 ligase CHIP. PLoS ONE. 2015. https:\/\/doi.org\/10.1371\/journal.pone.0128240.","DOI":"10.1371\/journal.pone.0128240"},{"key":"3720_CR50","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.jmb.2009.11.017","volume":"395","author":"L Kundrat","year":"2010","unstructured":"Kundrat L, Regan L. Identification of residues on Hsp70 and Hsp90 ubiquitinated by the cochaperone CHIP. J Mol Biol. 2010;395:587\u201394.","journal-title":"J Mol Biol"},{"key":"3720_CR51","doi-asserted-by":"crossref","unstructured":"Seo J, Han SY, Seong D, Han H-J, Song J. Multifaceted C-terminus of HSP70-interacting protein regulates tumorigenesis via protein quality control. Arch Pharm Res. 2019;42:63\u201375.","DOI":"10.1007\/s12272-018-1101-8"},{"key":"3720_CR52","doi-asserted-by":"publisher","unstructured":"Garcia AM, Davis AK, Martinez-Ramos C, Morishima Y, Lau M, Xu E, et al. High-throughput screening identifies a novel small-molecule modulator of Hsp70 that selectively enhances ubiquitination and degradation of misfolded neuronal NO synthase. Mol Pharmacol. 2025. https:\/\/doi.org\/10.1016\/j.molpha.2024.100008.","DOI":"10.1016\/j.molpha.2024.100008"},{"key":"3720_CR53","doi-asserted-by":"publisher","unstructured":"Huang X, Li Z, Zhang Q, Wang W, Li B, Wang L, et al. Circular RNA AKT3 upregulates PIK3R1 to enhance cisplatin resistance in gastric cancer via miR-198 suppression. Mol Cancer. 2019. https:\/\/doi.org\/10.1186\/s12943-019-0969-3.","DOI":"10.1186\/s12943-019-0969-3"},{"key":"3720_CR54","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1158\/0008-5472.CAN-15-2361","volume":"76","author":"D Mo","year":"2016","unstructured":"Mo D, Fang H, Niu K, Liu J, Wu M, Li S, et al. Human helicase RECQL4 drives Cisplatin resistance in gastric cancer by activating an AKT-YB1-MDR1 signaling pathway. Cancer Res. 2016;76:3057\u201366.","journal-title":"Cancer Res"},{"key":"3720_CR55","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.canlet.2016.01.056","volume":"374","author":"S Kumar","year":"2016","unstructured":"Kumar S, Stokes J III, Singh UP, Gunn KS, Acharya A, Manne U, et al. Targeting Hsp70: A possible therapy for cancer. Cancer Lett. 2016;374:156\u201366.","journal-title":"Cancer Lett"},{"key":"3720_CR56","doi-asserted-by":"crossref","unstructured":"Goloudina AR, Demidov ON, Garrido C. Inhibition of HSP70: a challenging anti-cancer strategy. Cancer Lett. 2012;325:117\u201324.","DOI":"10.1016\/j.canlet.2012.06.003"},{"key":"3720_CR57","doi-asserted-by":"crossref","unstructured":"Wang L, Jia Z, Xie D, Zhao T, Tan Z, Zhang S, et al. Methylation of HSP70 orchestrates its binding to and stabilization of BCL2 mRNA and renders pancreatic cancer cells resistant to therapeutics. Cancer Res. 2020;80:4500\u201313.","DOI":"10.1158\/0008-5472.CAN-19-1738"},{"key":"3720_CR58","doi-asserted-by":"crossref","unstructured":"Yang X, Wang J, Zhou Y, Wang Y, Wang S, Zhang W. Hsp70 promotes chemoresistance by blocking Bax mitochondrial translocation in ovarian cancer cells. Cancer Lett. 2012;321:137\u201343.","DOI":"10.1016\/j.canlet.2012.01.030"},{"key":"3720_CR59","doi-asserted-by":"crossref","unstructured":"Tang Q, Yuan Q, Li H, Wang W, Xie G, Zhu K, et al. MiR-223\/Hsp70\/JNK\/JUN\/miR-223 feedback loop modulates the chemoresistance of osteosarcoma to cisplatin. Biochem Biophys Res Commun. 2018;497:827\u201334.","DOI":"10.1016\/j.bbrc.2018.02.091"},{"key":"3720_CR60","doi-asserted-by":"crossref","unstructured":"He C, Poon C, Chan C, Yamada SD, Lin W. Nanoscale coordination polymers codeliver chemotherapeutics and siRNAs to eradicate tumors of cisplatin-resistant ovarian cancer. J Am Chem Soc. 2016;138:6010\u20139.","DOI":"10.1021\/jacs.6b02486"},{"key":"3720_CR61","doi-asserted-by":"crossref","unstructured":"Wei W, Lv P-P, Chen X-M, Yue Z-G, Fu Q, Liu S-Y, et al. Codelivery of mTERT siRNA and paclitaxel by chitosan-based nanoparticles promoted synergistic tumor suppression. Biomaterials. 2013;34:3912\u201323.","DOI":"10.1016\/j.biomaterials.2013.02.030"},{"key":"3720_CR62","doi-asserted-by":"publisher","unstructured":"Li Y, Li B, Chen C, Hou H, Su M, Li F, et al. Capturing Hydrophilic Chemotherapeutics Agents Into siRNA-Encapsulated Vesicle-Like Nanoparticles for Convenient ICB-Chemo Combination Therapy. Small. 2025. https:\/\/doi.org\/10.1002\/smll.202404073","DOI":"10.1002\/smll.202404073"},{"key":"3720_CR63","doi-asserted-by":"publisher","first-page":"34425","DOI":"10.1021\/acsnano.4c11259","volume":"18","author":"M Sanati","year":"2024","unstructured":"Sanati M, Figueroa-Espada CG, Han EL, Mitchell MJ, Yavari SA. Bioengineered nanomaterials for siRNA therapy of chemoresistant cancers. ACS Nano. 2024;18:34425\u201363.","journal-title":"ACS Nano"},{"key":"3720_CR64","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.apsb.2024.09.009","volume":"15","author":"MS Attia","year":"2025","unstructured":"Attia MS, Kijanka G, Nguyen N-T, Zhang J, An H. Advances and prospects of RNA delivery nanoplatforms for cancer therapy. Acta Pharm Sin B. 2025;15:52\u201396.","journal-title":"Acta Pharm Sin B"},{"key":"3720_CR65","doi-asserted-by":"publisher","unstructured":"Goyal R, Chopra H, Singh I, Dua K, Gautam RK. Insights on prospects of nano-siRNA based approaches in treatment of Cancer. Front Pharmacol. 2022. https:\/\/doi.org\/10.3389\/fphar.2022.985670","DOI":"10.3389\/fphar.2022.985670"},{"key":"3720_CR66","doi-asserted-by":"publisher","unstructured":"Loh KP, Ho D, Chiu GNC, Leong DT, Pastorin G. Chow EK-H: Clinical Applications of Carbon Nanomaterials in Diagnostics and Therapy. Adv Mater. 2018. https:\/\/doi.org\/10.1002\/adma.201802368.","DOI":"10.1002\/adma.201802368"},{"key":"3720_CR67","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.2147\/IJN.S488961","volume":"20","author":"Z Izadiyan","year":"2025","unstructured":"Izadiyan Z, Misran M, Kalantari K, Webster TJ, Kia P, Basrowi NA, et al. Advancements in liposomal nanomedicines: innovative formulations, therapeutic applications, and future directions in precision medicine. Int J Nanomedicine. 2025;20:1213\u201362.","journal-title":"Int J Nanomedicine"},{"key":"3720_CR68","doi-asserted-by":"publisher","unstructured":"Zhang Y, Li J, Pu K. Recent advances in dual- and multi-responsive nanomedicines for precision cancer therapy. Biomaterials. 2022. https:\/\/doi.org\/10.1016\/j.biomaterials.2022.121906","DOI":"10.1016\/j.biomaterials.2022.121906"},{"key":"3720_CR69","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1021\/acs.biomac.4c01257","volume":"26","author":"H Sun","year":"2024","unstructured":"Sun H, Zhong Z. Bioresponsive polymeric nanoparticles: from design, targeted therapy to cancer immunotherapy. Biomacromol. 2024;26:33\u201342.","journal-title":"Biomacromol"}],"updated-by":[{"DOI":"10.1186\/s12951-026-04118-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000}}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03720-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-025-03720-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03720-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T06:37:35Z","timestamp":1772174255000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-025-03720-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,11]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3720"],"URL":"https:\/\/doi.org\/10.1186\/s12951-025-03720-4","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,11]]},"assertion":[{"value":"29 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: Fig. 10 has been updated.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12951-026-04118-6","URL":"https:\/\/doi.org\/10.1186\/s12951-026-04118-6","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal research received approval from the Ethics Committee of the First Affiliated Hospital of Nanchang University (Ethics Number: CDYFY-IACUC-202309QR019). The Ethics Committee of the First Affiliated Hospital of Nanchang University approved the study, and all participants provided informed consent (Approval Number: (2025) CDYFYYLK (04\u2013030)).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"661"}}